Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
A randomised, double-blind, phase III efficacy and safety study of cediranib (RECENTIN™ ) when added to cisplatin plus a fluoropyrimidine, compared with cisplatin plus a fluoropyrimidine alone, in patients with previously untreated, locally advanced or metastatic, unresectable Gastric Cancer (GC) https://kusajili.com:443/Trial/Nw71ZvqrO028GIrsUnPA0Q%24a-randomised-double-blind-phase-iii-efficacy-and-safety-study-of-cediranib-recentint-when-added-to-cisplatin-plus-a-fluoropyrim
I have read and accept the terms of use of the site and the Privacy Policy
Send your message